Inhibition of PI3K and MEK: It is all about combinations and biomarkers

Brent N. Rexer, Ritwik Ghosh, Carlos L. Arteaga

Research output: Contribution to journalComment/debatepeer-review

34 Scopus citations


A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.

Original languageEnglish (US)
Pages (from-to)4518-4520
Number of pages3
JournalClinical Cancer Research
Issue number14
StatePublished - Jul 15 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Inhibition of PI3K and MEK: It is all about combinations and biomarkers'. Together they form a unique fingerprint.

Cite this